News

As per the agreement, which was originally signed on 11 July 2008, Nycomed is responsible for the development, manufacturing and commercialization of veltuzumab in the subcutaneous formulation to

The MAA, submitted under the name ‘TESAMORELIN FERRER,’ is based on the positive results from two Phase 3 clinical trials, which enrolled more than 800 patients, and follows

to BBB is applying the G- Technology for the delivery of doxorubicin for the treatment of brain cancer as its internal lead product 2B3 101. The company expects

Redwood’s technology was launched based on aldehyde tagging which functions as a chemical site on the surface of a protein that can be selectively modified through aldehyde specific

The patient recruitment has been started following the Argentinean approval which permits the company to recruit around eight patients with type 1 diabetes and severe hypoglycaemia. In the

In May this year Sanofi had signed a $613m licensing pact with Glenmark Pharmaceuticals Limited India (GPL) subsidiary Glenmark Pharmaceuticals SA (GPSA) to develop and commercialize a monoclonal

According to animal studies, amifostine protects against genomic instability and associated long term genomic damages resulting from radiation exposure, such as from CT scans and other diagnostic radiology

The company’s sBLA is supported by the results of a Phase 3 Study (‘147) investigating XGEVA versus placebo in 1,432 men with castrate-resistant prostate cancer. The results of

RP101, a first-in-class small molecule addressing chemo resistance in human cancers with initial focus on pancreatic carcinoma, is to be given in a combination with chemotherapy. Recently, RP101